{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T05:54:13Z","timestamp":1781589253104,"version":"3.54.5"},"reference-count":14,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) have transformed the therapeutic landscape of advanced non-small cell lung cancer (NSCLC), offering durable survival in selected patients. However, ICIs can induce immune-related adverse events (irAEs), among which pneumonitis represents one of the most clinically significant due to its potential severity and diagnostic challenges. Different radiological patterns have been reported, although they may overlap with infectious or radiation-induced lung injury, complicating a timely diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We report two cases of young patients with metastatic NSCLC and high PD-L1 expression who achieved long-term benefit from first-line pembrolizumab but were burdened by severe immune-related pneumonitis. Imaging findings in both patients were suggestive of organizing pneumonia associated with the presence of the so-called \u201catoll sign\u201d (or reversed halo sign), a radiological feature rarely reported in the context of ICI-related pneumonitis. In both cases, the diagnosis was supported by imaging, microbiological tests, and histology. The subsequent administration of high-dose steroids led to rapid relief of symptoms associated with radiological improvement. Despite pembrolizumab discontinuation, both patients maintained durable systemic disease control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These cases emphasize the importance of recognizing uncommon radiological patterns such as the atoll sign in patients receiving ICIs, highlighting the need for vigilance even after prolonged therapy and underscoring the potential for sustained oncologic benefit despite treatment discontinuation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1791312","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T05:38:47Z","timestamp":1781588327000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: The \u201catoll sign\u201d: a case series on an unusual radiological pattern of immune-mediated pneumonitis"],"prefix":"10.3389","volume":"17","author":[{"given":"Samuele","family":"Compagno","sequence":"first","affiliation":[{"name":"Department of Medical and Surgical Sciences, University of Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Di Federico","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, University of Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"De Giglio","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, University of Bologna","place":["Bologna, Italy"]},{"name":"Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Azienda Ospedaliero-Universitaria di Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Natali","sequence":"additional","affiliation":[{"name":"Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Azienda Ospedaliero-Universitaria di Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Abbate","sequence":"additional","affiliation":[{"name":"Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Azienda Ospedaliero-Universitaria di Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Ciccarese","sequence":"additional","affiliation":[{"name":"Department of Radiology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Azienda Ospedaliero-Universitaria di Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Giunchi","sequence":"additional","affiliation":[{"name":"Pathology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Azienda Ospedaliero-Universitaria di Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Riefolo","sequence":"additional","affiliation":[{"name":"Pathology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Azienda Ospedaliero-Universitaria di Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Dalpiaz","sequence":"additional","affiliation":[{"name":"Department of Radiology, Bellaria Hospital","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Damiani","sequence":"additional","affiliation":[{"name":"Pathology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Azienda Ospedaliero-Universitaria di Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Sperandi","sequence":"additional","affiliation":[{"name":"Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Azienda Ospedaliero-Universitaria di Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Candoli","sequence":"additional","affiliation":[{"name":"Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Azienda Ospedaliero-Universitaria di Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ardizzoni","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, University of Bologna","place":["Bologna, Italy"]},{"name":"Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Azienda Ospedaliero-Universitaria di Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Gelsomino","sequence":"additional","affiliation":[{"name":"Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Azienda Ospedaliero-Universitaria di Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"B1","volume-title":"Cancer Today","year":"2025"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2021.109617","article-title":"Expected and non-expected immune-related adverse events detectable by CT","volume":"138","author":"Ciccarese","year":"2021","journal-title":"Eur J Radiol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1148\/rg.2019190036","article-title":"Immune checkpoint inhibitor therapy\u2013related pneumonitis: Patterns and management","volume":"39","author":"Kalisz","year":"2019","journal-title":"RadioGraphics"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.180.5.1801251","article-title":"Reversed halo sign on high-resolution CT of cryptogenic organizing pneumonia: Diagnostic implications","volume":"180","author":"Kim","year":"2003","journal-title":"Am J Roentgenol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2500158","DOI":"10.1183\/13993003.00158-2025","article-title":"Update of the international multidisciplinary classification of the interstitial pneumonias: An ERS\/ATS statement","volume":"66","author":"Ryerson","year":"2025","journal-title":"Eur Respir J"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v11.i28.6938","article-title":"Pulmonary reversed halo cycles and consolidations after immunotherapy: A case report","volume":"11","author":"Suo","year":"2023","journal-title":"World J Clin cases"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14060613","article-title":"Pulmonary adverse events in cancer immunotherapy: Case studies of CT patterns","volume":"14","author":"Bocchini","year":"2024","journal-title":"Diagnostics"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2021203427","article-title":"Chest CT diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors: A position paper from the Fleischner Society","volume":"298","author":"Johkoh","year":"2021","journal-title":"Radiology"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2020-0280","article-title":"PD-L1 \u2265 50% lung cancer refractory to PD-1 inhibition: The role of salvage chemo-immunotherapy combination","volume":"13","author":"Gelsomino","year":"2021","journal-title":"Immunotherapy"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.03020","article-title":"Reversed halo sign: A systematic review","volume":"59","author":"Maturu","year":"2014","journal-title":"Respir Care"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2022.100441","article-title":"Clinical outcomes of patients with metastatic NSCLC after discontinuation of immunotherapy because of immune-related adverse effects","volume":"4","author":"Lievense","year":"2023","journal-title":"JTO Clin Res Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33984","article-title":"Long-term outcomes in patients with advanced and\/or metastatic non\u2013small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11)","volume":"128","author":"Kim","year":"2022","journal-title":"Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1791312\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T05:38:48Z","timestamp":1781588328000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1791312\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":14,"alternative-id":["10.3389\/fimmu.2026.1791312"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1791312","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"article-number":"1791312"}}